2 Biotech Stocks Trying to Double Today

PhaseBio and Dermira both reported upbeat drug data

Managing Editor
Mar 18, 2019 at 10:22 AM
facebook twitter linkedin

Two biotech stocks have nearly doubled in value today, and sit near the top of the Nasdaq. First up, PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) is up 75.3% to trade at $6.52, and earlier nabbed a record high of $8.88 -- more than double Friday's close of $3.72 -- after the company's appearance at the American College of Cardiology (ACC) conference this weekend. Specifically, PhaseBio's new data on its PB2452 drug were well-received. Mid-stage studies are set to begin later this year. 

This is set to be PHAS' best day ever by a wide margin. The drugmaker is now trading above its October $5 initial public offering (IPO) price for the first time since November.

Now, while the shares are in record-high territory, they have a ways to go to hit their average 12-month price target of $16.67. Echoing that, all four analysts following PHAS shares consider them a "buy" or better already.

Then there's Dermira Inc (NASDAQ:DERM), up 107% to trade at $14.16, and earlier hitting a new annual high of $14.91, after the company's eczema treatment met the main goal of its mid-stage study. Prior to today, the $9-$10 area had turned away DERM rallies in 2019. Now, the shares are on track to topple their 320-day moving average for the first time since January 2018, before a massive March bear gap. 

A short squeeze could provide more tailwinds for the equity. More than 10% of DERM's total available float is sold short, and it would take nearly a week for shorts to buy back their bearish bets, at the security's average pace of trading. 

There's been similar skepticism among options traders, judging by the security's Schaeffer's put/call open interest ratio (SOIR) of 1.00, which ranks 5 percentage points from an annual high. This shows a stronger-than-usual put-skew among near-term speculators. An exodus of option bears could also bee a boon for DERM.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1